Gastrointestinal neuroendocrine tumors treated with high dose octreotide-LAR: A systematic literature review
Open Access
- 1 January 2015
- journal article
- review article
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 21 (6), 1945-55
- https://doi.org/10.3748/wjg.v21.i6.1945
Abstract
AIM: To review literature on efficacy and safety of octreotide-long-acting repeatable (LAR) used at doses higher than the Food and Drug Administration (FDA)-approved 30 mg/mo for treatment of neuroendocrine tumors (NETs). METHODS: We searched PubMed and Cochrane Library from 1998-2012, 5 conferences (American Society of Clinical Oncology, Endocrine Society, European Neuroendocrine Tumor Society, European Society for Medical Oncology, North American Neuroendocrine Tumor Society) from 2000-2013 using MeSH and keyterms including neuroendocrine tumors, carcinoid tumor, carcinoma, neuroendocrine, and octreotide. Bibliographies of accepted articles were also searched. Two reviewers reviewed titles, abstracts, and full-length articles. Studies that reported data on efficacy and safety of ≥ 30 mg/mo octreotide-LAR for NETs in human subjects, published in any language were included in the review. RESULTS: The search identified 1086 publications, of which 238 underwent full-text review (20 were translated into English); 17 were included in the review. Studies varied in designs, subjects, octreotide-LAR regimens, and definition of outcomes. Eleven studies reported use of higher doses to control symptoms and tumor progression, although symptom severity and formal quality-of-life analysis were not quantitatively measured. Ten studies reported efficacy, describing 260 subjects with doses ranging from 40 mg/mo or 30 mg/3 wk up to 120 mg/mo. Eight studies reported expert clinical opinion that supported dose escalation of octreotide-LAR up to 60 mg/mo for symptom control and suggested increased doses may be effective at preventing tumor progression. Eight studies reported safety; there was no evidence of increased toxicity associated with doses of octreotide-LAR > 30 mg/mo. CONCLUSION: As reported in this review, octreotide-LAR at doses > 30 mg/mo is being prescribed for symptom and tumor control in NET patients. Furthermore, expert clinical opinion provided support for escalation of somatostatin analogs for refractory hormonal symptoms.Keywords
This publication has 15 references indexed in Scilit:
- Above-Label Doses of Octreotide-LAR in Patients With Metastatic Small Intestinal Carcinoid Tumors.2013
- Systemic Treatment in Unresectable Metastatic Well-Differentiated Carcinoid TumorsPancreas, 2013
- Evaluating the Characteristics and the Management of Patients With Neuroendocrine Tumors Receiving Octreotide LAR During a 6-Year PeriodPancreas, 2011
- Safety review: Dose optimization of somatostatin analogs in patients with acromegaly and neuroendocrine tumorsAdvances in Therapy, 2011
- Shortened interval of long-acting octreotide administration is effective in patients with well-differentiated neuroendocrine carcinomas in progression on standard dosesPublished by Springer Science and Business Media LLC ,2011
- NANETS Consensus Guidelines for the Diagnosis of Neuroendocrine TumorPancreas, 2010
- Somatostatin Analogues: Treatment of Pituitary and Neuroendocrine TumorsProgress in Brain Research, 2010
- Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study GroupJournal of Clinical Oncology, 2009
- Octreotide LAR in CarcinoidPancreas, 2008
- Validation of Serum Versus Plasma Measurements of Chromogranin A Levels in Patients With Carcinoid TumorsPancreas, 2006